Brentuximab vedotin regimen extends survival in advanced DLBCL
Click Here to Manage Email Alerts
The addition of brentuximab vedotin to lenalidomide and rituximab extended OS among patients with relapsed or refractory diffuse large B-cell lymphoma, according to the agent’s manufacturer.
The three-agent combination also extended PFS and increased overall response rate.
Brentuximab vedotin (Adcetris, Pfizer) is an antibody-drug conjugate comprised of a CD30-directed monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.
Brentuximab vedotin is approved for seven indications in the United States — six for adults and one for children.
The randomized phase 3 ECHELON-3 trial assessed the efficacy and safety of lenalidomide and rituximab (Rituxan; Genentech, Biogen) plus either brentuximab vedotin or placebo for 230 adults with relapsed/refractory diffuse large B-cell lymphoma.
Study participants had received at least two prior lines of therapy and were ineligible for stem cell transplant for chimeric antigen receptor T-cell therapy.
Researchers enrolled patients across North America, Europe and the Asia-Pacific region regardless of CD30 expression.
Results showed the brentuximab vedotin regimen improved OS — the study’s primary endpoint — as well as in the key secondary endpoints included PFS and ORR.
The safety and tolerability of brentuximab vedotin appeared consistent with the agent’s use for patients with relapsed or refractory DLBCL.
“This is the third phase 3 study in a type of lymphoma to demonstrate an overall survival benefit for an Adcetris combination. Based on the strong results from ECHELON-3, we’re excited that Adcetris could address an area of high unmet need in patients with relapsed or refractory DLBCL, irrespective of CD30 expression,” Roger Dansey, MD, chief development officer of oncology at Pfizer, said in a press release. “The results are particularly encouraging because the study evaluated heavily pretreated patients, including some who received prior CAR-T therapy.”
Complete data from the trial will be presented at a medical meeting, according to the release.
Read more about
Click Here to Manage Email Alerts